consid
wider
repercuss
action
accept
ecolog
system
pressur
caus
evolut
also
case
antimicrobi
result
develop
resist
therapeut
failur
drug
extent
amelior
advanc
pharmaceut
industri
stop
us
critic
apprais
use
modifi
behavior
slow
process
prescrib
human
medicin
veterinari
medicin
farm
consid
question
allianc
prudent
use
antimicrobi
apua
approach
review
situat
recommend
includ
decreas
prescrib
antibacteri
nonbacteri
infect
uk
initi
call
path
least
resist
encourag
gener
practition
avoid
prescrib
reduc
durat
prescript
condit
upper
respiratori
tract
infect
uncompl
urinari
tract
infect
approach
success
anoth
recommend
reduc
prescrib
broad
spectrum
antibacteri
uk
hospit
problem
identifi
inappropri
use
antibacteri
insuffici
train
infecti
diseas
difficulti
select
empir
antibacteri
therapi
poor
use
avail
microbiolog
inform
fear
litig
fact
major
antibacteri
prescrib
least
experienc
doctor
close
liaison
laboratori
clinician
develop
local
protocol
address
anoth
recommend
tighten
use
antibacteri
prophylaxi
improv
patient
complianc
combin
improv
educ
doctor
patient
improv
commun
skill
problem
address
recommend
encourag
teach
method
modifi
prescrib
habit
shown
workshop
led
signific
reduct
prescrib
broadspectrum
antibacteri
commun
audit
prescrib
antibacteri
also
recommend
surveil
system
around
world
monitor
trend
resist
european
antimicrobi
resist
surveil
progamm
earss
monitor
antibacteri
resist
intern
union
tuberculosi
lung
diseas
collabor
monitor
tuberculosi
intern
aid
societi
monitor
hiv
third
world
bigger
problem
resist
whether
drug
even
effect
often
spoil
climact
condit
poor
qualiti
gener
counterfeit
drug
common
also
patient
may
abl
complet
cours
financi
reason
fact
antimicrobi
resist
anim
agricultur
impact
resist
faair
commiss
apua
conclud
nonhuman
use
antibacteri
lead
develop
antibacteri
resist
human
pathogen
european
commiss
ban
use
antibacteri
growth
promot
western
world
improv
diagnosi
sepsi
access
local
guidelin
consid
withhold
treatment
pend
investig
decid
treatment
stop
earlier
treat
patient
result
mani
develop
countri
need
improv
access
antimicrobi
prefer
control
environ
appropri
medic
advic
need
relearn
use
antibiot
prudent
use
antibiot
apua
europeadvoc
control
applic
anan
societi
clinic
microbiolog
infecti
tibiot
therapeut
use
strain
diseas
escmid
author
made
suscept
drug
reemerg
dr
stuart
recommend
work
partnership
levi
presid
allianc
prudent
use
context
act
steward
antibiot
apua
intern
level
also
nation
paper
concern
chang
local
steward
sticht
werkgroep
antibith
attitud
prescrib
consum
oticabeleid
swab
netherland
regard
use
antimicrobi
problem
swedish
strateg
programm
ration
use
resist
poor
qualiti
use
establish
antimicrobi
agent
surveil
resisthat
associ
antibacteri
use
tanc
strama
us
equival
would
preval
resist
whether
antibacb
infecti
diseas
societi
america
idteri
control
measur
today
reduc
level
sa
center
communic
diseas
conresist
clear
trol
prevent
cdc
european
centr
diseas
prevent
control
ecdc
new
european
union
agenc
open
provid
stewardship
europ
infect
use
antimicrobi
widerang
includ
influenza
sever
acut
respiratori
syndiff
countri
countri
condrom
sar
hiv
uk
clinician
sume
human
medicin
veterinari
medicin
follow
local
guidelin
refer
establish
anim
farm
agricultur
us
refer
monthli
index
medic
quot
antibacteri
use
specialti
mim
british
nation
formuhuman
medicin
use
comlari
bnf
muniti
hospit
suggest
dose
calcul
weight
age
chilthat
prescrib
unnecessari
veteridren
standard
gener
use
nari
farm
use
account
remain
otherwis
healthi
adult
prescrib
schedul
therapeut
establish
popul
studi
prophylact
growth
promot
purpos
usag
question
tend
group
variabl
togeth
evid
target
organ
differ
minimum
key
reduc
inappropri
use
aninhibitori
concentr
tibacteri
develop
guidelin
prescrib
pharmacokinet
drug
differ
differthat
gener
maximum
health
gain
minimum
develop
resist
allianc
ent
patient
result
unlucki
individu
infect
resist
organ
reduc
prescript
antibacteri
inin
peak
concentr
area
fection
bacteri
ie
viral
upper
respirth
curv
reduc
may
treatment
failur
atori
tract
infect
result
subtherapeut
antibacteri
concentr
reduc
overprescript
broadspectrum
site
infect
extent
problem
antibacteri
contribut
global
problem
tighten
use
antibacteri
prophylact
crobial
resist
yet
establish
situat
especi
respect
time
feel
like
highli
signific
select
durat
resist
strain
encourag
patient
complianc
prescript
includ
address
hoard
antibacteri
use
antibacteri
outsid
standard
regifor
futur
use
men
prescrib
longterm
lowdos
review
use
antimicrobialcontain
cleanment
also
problemat
guillemot
carbon
er
disinfect
show
convincingli
led
increas
likelihood
penicillinresist
pneumococci
promot
use
nonantimicrobi
intervenemerg
children
hand
finisht
condom
bed
net
without
ing
cours
antibacteri
may
bad
thing
insecticid
impregn
vaccin
provid
relaps
infect
avoid
even
encourag
form
teach
like
adequ
dosag
prolong
cours
breed
result
modif
prescrib
behaviour
resist
therefor
tradit
advic
includ
interact
repeat
teach
se
keep
take
tablet
longer
appropri
sion
workshop
problemsolv
session
wish
develop
global
strategi
use
audit
monitor
prescrib
behaviour
contain
antimicrobi
resist
medicin
guidelin
prosought
synthesi
recommend
expert
duce
evid
base
apua
propolici
group
approach
apua
duce
comprehens
framework
folrecommend
base
follow
four
low
good
clinic
govern
facet
evid
base
behind
recommend
may
establish
effect
surveil
sysnot
confirm
randomis
clinic
trial
tem
assess
shift
antibacteri
resist
repres
synthesi
expert
opinion
common
pattern
local
nation
global
scale
sens
use
inform
guid
prescrib
issu
antibacteri
drug
appropri
use
antimicrobi
fear
perceiv
rather
real
health
risk
lead
alter
patient
provid
behaviour
clinician
overprescrib
broadspectrum
agent
reduc
inappropri
use
antimicrobi
instead
observ
clinic
develop
agent
symptom
pend
result
bacteriolog
encourag
research
develop
vestig
nonbiomed
reason
new
antimicrobi
agent
address
overprescript
antibacteri
investiproblem
establish
resist
organ
gate
lam
lam
found
treat
infect
caus
surveilpubl
sector
antibacteri
often
prescrib
lanc
indic
may
caus
futur
diseas
timesav
measur
privat
sector
recognis
use
antibacteri
outsid
often
prescrib
fear
lose
client
human
medicin
compar
quantiti
use
summaris
relationship
use
farm
industri
veterinari
practic
antibacteri
develop
resist
impact
human
health
human
ecosystem
live
probassess
lemat
current
prescrib
pattern
indic
recommend
apua
antimiproblem
improv
good
control
crobial
prescrib
influenc
folstewardship
need
consid
chang
low
pattern
establish
improv
prereduc
overprescript
scribe
pattern
improv
qualiti
use
broadspectrum
antibacteri
reduc
resist
broadspectrum
antibacteri
amoxicillinclavulan
acid
cefotaxim
tend
exampl
differ
situat
scribe
patient
deem
septic
global
scale
correct
inadequ
initi
therapi
compromis
patient
outcom
medic
surgic
ward
howev
fever
due
infec
tion
infect
sever
assess
criticountri
use
uk
exampl
cal
patient
hospit
day
possibl
resist
bacteri
infect
consid
extendedspectrum
anof
antibacteri
prescrib
genertibacteri
may
consid
patient
al
practic
prescrib
respiramrsa
recent
appear
septic
tori
tract
infect
second
common
antibacteri
activ
mrsa
vancoreason
prescript
urinari
tract
infect
mycin
teicoplanin
linezolid
also
considth
common
hospit
pathogen
tend
show
ere
resist
antibiogram
consist
meticillinresist
staphylococcu
aureu
mrsa
reduc
overprescript
broadspecassort
gramneg
bacilli
trum
antibacteri
hospit
set
problemat
presenc
longterm
prostheclos
liaison
microbiologist
clinisi
central
line
cathet
patient
cian
regard
posit
cultur
expos
broadspectrum
antibacteri
ask
advic
aim
stop
narrow
gener
accept
someon
develop
spectrum
antibacteri
use
soon
hospitalacquir
infect
sepsi
develop
investig
indic
appropri
treatment
hour
admiss
may
whole
impact
intervent
substanti
could
poor
delay
commun
result
follow
paragraph
discuss
high
prescrib
rate
antibacteri
done
uk
alter
prescrib
behaviour
use
critic
ill
patient
intens
care
unit
apua
eight
recommend
framework
icu
combin
ward
round
facilit
see
section
appropri
prescrib
uptod
result
may
yet
avail
comput
antibacteri
committe
compris
mi
crobiologist
infecti
diseas
clinician
reduc
prescript
antibacteri
infecpharmacist
gener
list
restrict
antibacterit
bacteri
ie
viral
upper
respirato
prescrib
consult
ry
tract
infect
commun
establish
local
protocol
approin
name
path
least
resist
priat
firstlin
antibacteri
given
clinic
advic
prescrib
antibacteri
sore
scenario
target
like
pathogen
throat
cough
cold
limit
prescrib
knowledg
local
sensit
pattern
anuncompl
urinari
tract
infect
healthi
tibacteri
formulari
review
period
anwomen
day
limit
telephon
preother
approach
often
consid
mandatori
rescrib
antibacteri
appear
view
intraven
antibacteri
prescrib
effect
antibacteri
prescrib
rate
hour
mainli
avoid
inappropricommun
fallen
england
milat
long
cours
intraven
therapi
also
lion
script
per
year
million
serv
prompt
review
posit
microbioth
largest
decreas
seen
prescript
logic
result
like
pathogen
children
isol
respons
clinician
encourag
form
teach
modifi
rationalis
therapi
area
prescrib
behaviour
room
improv
recognis
didact
teach
problem
identifi
hospit
lead
work
well
problemsolv
workshop
modinappropri
use
antibacteri
includ
insuffiifi
prescrib
behaviour
studi
shown
cient
train
infecti
diseas
difficulti
antibacteri
workshop
led
select
appropri
antibacteri
empirireduct
prescrib
broadspectrum
calli
insuffici
use
microbiolog
informaantibacteri
commun
hospit
ention
avail
fear
litig
also
viron
especi
teach
hospit
major
antibacteri
prescrib
least
conduc
ongo
learn
isolatexperienc
doctor
ed
doctor
perhap
gener
practic
might
tighten
use
prophylact
antibacteri
easi
keep
date
howev
advent
websit
guidelin
even
disparito
tighten
use
antibacteri
prophylaxti
unrealist
expect
doctor
date
reeduc
junior
surgeon
annual
thing
reason
keep
basi
goe
way
toward
address
abreast
current
guidelin
drug
mean
control
problem
includ
commonli
prescrib
includ
inappropri
time
durat
administr
antibacteri
scottish
execut
britalong
confus
appropri
ish
societi
antimicrobi
chemotherapi
bsac
agent
agent
use
scottish
intercollegi
fund
websit
medic
undergradu
guidelin
network
sign
guidelin
learn
prudent
prescrib
antibacteri
allow
input
local
data
assess
approthrough
framework
learn
object
priat
prophylaxi
local
situat
reflect
learn
webbas
format
call
appropri
antibiot
prescrib
tomorrow
improv
patient
complianc
antibacteridoctor
apt
al
commun
patient
educ
use
audit
monitor
prescrib
habit
improv
commun
skill
area
success
databas
keep
record
antibacbeen
highlight
undergradu
postgraduteri
prescrib
retrospect
analys
ate
level
uk
last
year
way
individu
depart
receiv
introduct
roleplay
scenario
play
feedback
modifi
prescrib
habit
apback
video
record
consult
multimedia
edupropri
computeris
prescrib
allow
easic
campaign
carri
uk
er
audit
without
interf
prescrib
twophas
campaign
first
process
recent
europeanwid
audit
hospit
phase
autumn
support
health
proantibacteri
prescrib
access
wwfession
manag
acut
upper
respirawabdnacukarpac
tori
tract
infect
reduc
patient
expect
prescript
encourag
use
ideal
world
everyon
bacteri
infecsymptomat
relief
second
protion
requir
antibacteri
would
firm
mote
messag
antibacteri
kill
good
microbiolog
diagnosi
narrowbacteria
keep
us
healthi
use
combin
spectrum
antibacteri
commenc
minimum
press
magazin
media
relat
durat
requir
cure
current
provid
resourc
pack
school
health
ausitu
degre
pragmat
requir
thoriti
nonprescript
pad
gener
pracresult
major
patient
receiv
appropritition
hospit
ate
antibacteri
therapi
apua
fifth
sixth
recommend
give
indic
problem
clinic
use
antimicrobialcontain
cleaner
nonrelev
resist
pathogen
europ
useantimicrobi
intervent
prescrib
inform
european
antimicrobi
re
address
sistanc
surveil
programm
earss
websit
wwwearssrivmnl
antibiot
resist
test
conjunct
nation
area
antiprevent
control
arpac
websit
www
tuberculosi
treatmentresist
surveil
abdnacukarpac
earss
intern
netth
aim
project
estim
magwork
nation
surveil
system
collect
nitud
pattern
antituberculosi
treatment
recompar
valid
antimicrobi
susceptibilisist
monitor
trend
evalu
effect
ty
data
public
health
action
collect
informatreat
programm
plan
evalu
intervent
streptococcu
pneumonia
aureu
estion
prevent
programm
aid
develop
cherichia
coli
enterococcu
faecali
e
faecituberculosi
polici
countri
level
strengthen
um
identifi
caus
invas
laboratori
servic
advoc
increas
polit
diseas
collect
data
laboratori
servcommit
identifi
research
need
ing
hospit
countri
amass
antivir
data
isol
coordin
commonli
prescrib
antivir
treatdutch
nation
institut
public
health
ment
hiv
highli
activ
antiretrovir
therapi
environ
rivm
haart
consist
two
nucleosid
revers
earss
data
pneumonia
caus
invatranscriptas
inhibitor
either
nonnucleosid
sive
diseas
analys
assess
trend
resisrevers
transcriptas
inhibitor
one
two
proteas
tanc
penicillin
erythromycin
inhibitor
british
hiv
associ
bhiva
overal
resist
penicillin
produc
treatment
guidelin
possibl
erythromycin
decreas
carri
resist
test
patient
poor
penicillin
resist
per
annum
increas
complianc
tend
select
resist
viin
erythromycin
resist
per
annum
ruse
result
increas
viral
load
increas
dual
resist
per
annum
treatment
failur
along
increas
earss
predict
infect
resist
viru
increasingresist
erythromycin
dual
resisli
common
problem
global
hiv
treatmentt
arpac
deal
much
broader
selecresist
surveil
network
anoth
tion
resist
bacteria
specif
regard
hosstrategi
contain
antimicrobi
resispit
infect
control
antibacteri
tanc
prescrib
infect
control
polici
treatment
tuberculosi
hiv
common
longer
durat
therapi
compar
infect
make
patient
complianc
incid
tuberculosi
uk
low
control
advers
effect
import
thank
highli
effect
nation
control
polici
patient
come
oversea
human
medicin
develop
countri
origin
relev
may
countri
use
subsaharan
africa
like
multidrugresist
tuberculoan
exampl
si
situat
secondlin
agent
use
directli
observ
therapi
use
enth
major
morbid
mortal
develsur
treatment
taken
greater
releop
countri
children
year
old
vanc
undevelop
countri
peopl
may
die
lower
respiratori
tract
infect
malaria
less
inclin
complet
treatment
cours
bacillari
dysenteri
measl
well
malnutrithey
start
feel
better
tion
signific
infecti
diseas
includ
hiv
tuberculosi
global
project
antituberculosi
treatmentresist
surveil
place
sinc
devis
integr
manageit
collabor
interna
childhood
ill
imci
syntion
union
tuberculosi
lung
disdrom
approach
clinic
manag
aneas
partner
form
network
timicrobi
use
would
depend
govern
polsupran
laboratori
aid
nation
refer
ici
rang
antimicrobi
limit
laboratori
qualiti
assur
suscept
laboratori
servic
somewhat
lack
govern
respons
ensur
knowlsafeti
address
threat
antibiot
sensit
edg
local
antimicrobi
sensit
pattern
prevent
control
zoonot
emerg
infecavail
dissemin
district
medic
tiou
diseas
protect
environ
ecosysoffic
dmo
nongovernment
agenc
tem
particip
bioand
agroterror
prework
area
liais
dmo
pared
respons
use
skill
conand
adher
nation
guidelin
front
nonzoonot
diseas
malaria
hiv
aid
vaccin
prevent
diseas
chronic
diseasmost
importantli
must
ensur
es
injuri
strengthen
publichealth
inmedicin
still
efficaci
transport
frastructur
advanc
medic
scienc
given
climact
condit
temperatur
research
contain
expos
sun
may
rise
spoil
antibacteri
appear
counterfeit
veterinari
practic
use
equival
quantiti
drug
poor
qualiti
gener
avail
antimicrobi
human
medicin
mainli
antibacteri
bought
counter
otc
growth
promot
diseas
prevent
common
ad
morbid
countri
countertherapeut
use
includ
treat
mastiti
dairi
feit
gener
drug
may
less
efficaci
cattl
respiratori
ill
batteryrear
otc
antibiot
may
taken
short
time
chicken
nontherapeut
use
includ
growth
proin
low
dosag
expens
motion
chicken
agricultur
streptomycin
background
document
global
oxytetracyclin
use
spray
fruit
orchard
strategi
contain
antimicrobi
resismak
visual
appeal
investig
tanc
call
drug
resist
malaria
conclud
situat
apua
initi
peopl
need
access
antimalari
project
call
fact
antimicrobi
resist
accept
lead
increas
level
anim
agricultur
impact
resist
must
also
invest
conresist
faair
concern
trol
measur
increas
use
lifespan
overal
effect
antimicrobi
use
ecologitherapi
allow
time
new
treatment
cal
point
view
two
way
consid
control
develop
resist
infect
acquir
problem
prescrib
tuberculosi
environ
first
direct
infect
complianc
therapi
feel
stronghuman
pathogen
bacteria
salmonella
ly
advis
commenc
chicken
second
human
acquisitreat
supervis
full
durat
tion
resist
nonpathogen
bacteria
therapi
assur
usual
month
environ
act
reservoir
resisi
particular
relev
refuge
set
tanc
gene
mayb
transfer
human
pathoth
use
nonantimicrobi
intervent
genic
bacteria
find
conclus
mainli
target
malaria
bed
net
hiv
antimicrobi
use
select
resist
bacteri
strain
lowpric
condom
nation
vaccinaand
genet
vector
specifi
resist
gene
tion
programm
incorpor
imauthor
see
propag
antimicrobi
resisci
tanc
ecolog
problem
suggest
reduc
would
requir
understand
nonhuman
use
antimicrobi
commens
microbiota
mammal
genet
vector
resist
one
antimicrobi
dr
calvin
schwabe
talk
one
medicin
select
resist
genet
linkag
bring
togeth
human
veterinari
resist
gene
antimicrobi
resist
medicin
human
health
provid
mostlog
emerg
period
use
unifi
apic
caus
veterinari
medicin
antimicrobi
emerg
resist
varhierarchi
valu
veterinarian
aspect
i
preval
reach
certain
level
profess
opportun
respons
revers
difficult
effect
global
protect
health
wellb
peopl
problem
antimicrobi
resist
unknown
includ
protect
food
secur
faair
conclus
antimicrobi
use
anywher
anyth
affect
anyon
anyprescrib
attitud
cover
spectrum
conwher
world
cost
us
financi
serv
aggress
use
antimicrobi
health
may
affect
although
popul
easili
justifi
lifethreaten
condit
level
cost
antibacteri
resist
often
prescrib
reduc
morbid
known
therefor
elimin
nontheraprev
occasion
complic
word
peutic
use
antimicrobi
food
anim
doctor
deriv
greek
word
teachagricultur
benefit
us
european
comer
import
educ
patient
mission
ban
use
antibacteri
growth
condit
fear
usual
result
promot
ignor
reassur
address
problem
occur
recur
forgotsever
group
look
way
evalu
ten
develop
countri
influenc
safeti
ingest
antimicrobi
residu
use
prescrib
five
way
veterinari
medicin
human
intestin
microflora
one
group
identifi
presenc
improv
diagnosi
sepsi
multidrugresist
enter
bacteria
dairi
farm
access
latest
local
guidelin
subject
topsoil
implic
reservoir
decid
antimicrobi
treatment
withheld
al
resist
clinic
relev
antibacteripend
posit
microbiolog
al
problem
resist
decid
treatment
stop
rationalis
compound
handl
wast
food
result
return
chase
result
anim
often
pollut
widespread
area
receiv
time
contamin
water
suppli
food
anim
may
treat
patient
result
also
develop
antibacterialresist
diseas
advanc
inform
technolog
near
scale
problem
ascertain
patient
test
could
also
improv
prescrib
behamechan
increas
diseas
human
viour
antimicrobi
resist
anim
multifactori
mani
develop
countri
need
improv
acand
includ
increas
colonis
rate
cess
antimicrobi
prefer
conincreas
pathogen
decreas
effitrol
environ
appropri
medic
advic
caci
treatment
